MLL-rearranged leukemias—an update on science and clinical approaches
AC Winters, KM Bernt - Frontiers in pediatrics, 2017 - frontiersin.org
The mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of …
How I treat infant leukemia
Leukemia in infants is rare but generates tremendous interest due to its aggressive clinical
presentation in a uniquely vulnerable host, its poor response to current therapies, and its …
presentation in a uniquely vulnerable host, its poor response to current therapies, and its …
Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized …
R Pieters, P De Lorenzo, P Ancliffe… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL)
gene rearrangements and coexpression of myeloid markers. The Interfant-06 study …
gene rearrangements and coexpression of myeloid markers. The Interfant-06 study …
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal
prognosis. Survival outcomes have remained static in recent decades despite treatment …
prognosis. Survival outcomes have remained static in recent decades despite treatment …
New approaches to the management of adult acute lymphoblastic leukemia
R Bassan, JP Bourquin, DJ DeAngelo… - Journal of Clinical …, 2018 - ascopubs.org
Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic
hematopoietic cell transplantation, result in an overall survival of approximately 40%, a …
hematopoietic cell transplantation, result in an overall survival of approximately 40%, a …
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory
type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we …
type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we …
A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation
M Qayed, KW Ahn, CL Kitko… - Blood, The Journal …, 2021 - ashpublications.org
A disease risk index (DRI) that was developed for adults with hematologic malignancy who
were undergoing hematopoietic cell transplantation is also being used to stratify children …
were undergoing hematopoietic cell transplantation is also being used to stratify children …
The combination of curaxin CBL0137 and histone deacetylase inhibitor panobinostat delays KMT2A-rearranged leukemia progression
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in
approximately 10% of acute leukemias and characteristically define disease with poor …
approximately 10% of acute leukemias and characteristically define disease with poor …
Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin
M Karsa, A Kosciolek, A Bongers, A Mariana… - British Journal of …, 2021 - nature.com
Background The prognosis for high-risk childhood acute leukaemias remains dismal and
established treatment protocols often cause long-term side effects in survivors. This study …
established treatment protocols often cause long-term side effects in survivors. This study …
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia
K Somers, K Evans, L Cheung, M Karsa, T Pritchard… - Leukemia, 2020 - nature.com
The prognosis for children diagnosed with high-risk acute lymphoblastic leukemia (ALL)
remains suboptimal, and more potent and less toxic treatments are urgently needed. We …
remains suboptimal, and more potent and less toxic treatments are urgently needed. We …